Immunotherapy and targeted drugs could stop some melanomas from returningCancer Research UKIn Checkmate 238, patients were also given either nivolumab or another immunotherapy drug called ipilumumab (Yervoy), which has already been trialled for this gr… Continue reading
The Rockefeller University NewswireIn brief: Alternative CRISPR system is less specific, more robustThe Rockefeller University NewswireThe genetic tool adept at line-by-line gene editing, CRISPR, has revolutionized the ability of scientists to manipula… Continue reading
|
Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine
Labiotech.eu (blog) PCI Biotech’s T cell-stimulating vaccine enhances the cellular immune response, supporting it as a candidate for use alongside cancer vaccines. PCI Biotech, based in Oslo, Norway, has seen … photochemical internalization (PCI) technology. A … |
Medscape |
FDA Extends Holds in Immunotherapy Trials in Blood Cancers
Medscape Because of safety concerns, the US Food and Drug Administration has placed full or partial holds on clinical trials of three immunotherapies — pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, BMS), and durvalumab (Imfinzi, AstraZeneca) — that are … |
Newsmax |
Immunotherapy Also Good for Early-Stage Cancers
Newsmax Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors. The latest research shared with 23,000 experts at Europe’s top oncology meeting shows how medicines that have … Cancer Immunotherapy Useful at Initial StagesThe Global Health News (press release) (blog) Cancer mutation gains ground as test for immunotherapy drugsSaudi Gazette ESMO 2017 round up: BMS and AZ bounce backpharmaphorum |
|
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type …
Markets Insider The initiation of this natural history study brings us one step closer to our goal of making a CRISPR-based medicine available to people with significant vision loss caused by LCA10,” said Gerry Cox, M.D., Ph.D., Chief Medical Officer, Editas Medicine. |
|
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type …
Markets Insider The initiation of this natural history study brings us one step closer to our goal of making a CRISPR-based medicine available to people with significant vision loss caused by LCA10,” said Gerry Cox, M.D., Ph.D., Chief Medical Officer, Editas Medicine. |